Pamrevlumab for the treatment of DMD
FibroGen receives Fast Track designation from the U.S. FDA for Pamrevlumab to treat Duchenne muscular dystrophy (DMD). April 12, 2021, Original press release. Source: FibroGen, Inc FibroGen, Inc. announced […]
Solid Biosciences reports efficacy and safety data
Solid Biosciences reports efficacy and safety data from the ongoing IGNITE DMD clinical trial and resumption of patient dosing in the 2E14 VG/kg cohort. La Force is sharing this press […]
Article about DMD in Nature.com
Recent studies on Duchenne muscular dystrophy (DMD) have greatly deepened our understanding of the primary and secondary pathogenetic mechanisms. Guidelines for the multidisciplinary care for DMD that address obtaining a […]
News from Vamorolone in Duchenne Muscular Dystrophy
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy Original Press release > Pratteln, Switzerland, March 3, 2021 Santhera Pharmaceuticals announces that […]
FDA Approval of AMONDYS 45 (casimersen)
Sarepta Therapeutics announces FDA approval of AMONDYS 45 (casimersen) injection to treat Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 45. Feb. 25, 2021, >Original press release< Sarepta […]
Italfarmaco provides an update on Givinostat
Italfarmaco provides an update on Givinostat, an ongoing clinical program, in an oral presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy. Feb. 22, 2021, > Original press release […]
